{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:25:44Z","timestamp":1761128744574},"reference-count":67,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,5,12]],"date-time":"2009-05-12T00:00:00Z","timestamp":1242086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:p><jats:bold>Objectives\n\t\t\t\t\t<\/jats:bold> Zidovudine (ZDV) has been the cornerstone of antiretroviral (ARV) therapy for pregnant women infected with HIV\u20101 in the prevention of mother\u2010to\u2010child transmission (MTCT) and remains the only licensed ARV for use in pregnancy. We explored the current and future roles of tenofovir disoproxil fumarate (TDF) in the prevention of MTCT of HIV\u20101.<\/jats:p><jats:p><jats:bold>Methods\n\t\t\t\t\t<\/jats:bold> We reviewed the published literature by conducting database searches of <jats:italic>in vitro<\/jats:italic>, animal and clinical studies, reported in journals and at conferences, using the search terms Tenofovir\/gs4331\/viread, pregnant\/pregnancy, lactate, lactation, natal, reproduce\/reproduction, placenta\/placental, malformation, and teratogenicity\/teratogenic.<\/jats:p><jats:p><jats:bold>Results\n\t\t\t\t\t<\/jats:bold> In a macaque model, perinatal exposure to very high dose tenofovir resulted in bone toxicity in some offspring. However, perinatal use of TDF, both single dose and as part of highly active antiretroviral therapy in women, has been well tolerated in the short term by mothers and their infants. Further, the addition of single\u2010dose TDF to single\u2010dose nevirapine (SD\u2010NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance.<\/jats:p><jats:p><jats:bold>Conclusions\n\t\t\t\t\t<\/jats:bold> The addition of TDF to SD\u2010NVP reduces NNRTI resistance. The role of TDF in this setting and during pregnancy for reducing rates of MTCT requires investigation. While short\u2010term toxicity data are encouraging, long\u2010term follow\u2010up of exposed mothers and infants is required.<\/jats:p>","DOI":"10.1111\/j.1468-1293.2009.00709.x","type":"journal-article","created":{"date-parts":[[2009,5,13]],"date-time":"2009-05-13T01:31:33Z","timestamp":1242178293000},"page":"397-406","source":"Crossref","is-referenced-by-count":25,"title":["Tenofovir disoproxil fumarate in pregnancy and prevention of mother\u2010to\u2010child transmission of HIV\u20101: is it time to move on from zidovudine?"],"prefix":"10.1111","volume":"10","author":[{"given":"C","family":"Foster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Lyall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Olmscheid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DM","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,7,8]]},"reference":[{"key":"e_1_2_13_2_2","doi-asserted-by":"crossref","unstructured":"Gazzard BG on behalf of the BHIVA Treatment Guidelines Writing Group.British HIV Association guidelines for the treatment of HIV\u20101\u2010infected adults with antiretroviral therapy 2008.HIV Med2008;9:563\u2013608.","DOI":"10.1111\/j.1468-1293.2008.00636.x"},{"key":"e_1_2_13_3_2","unstructured":"European AIDS Clinical Society.Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. June 2008. Available at:http:\/\/www.europeanaidsclinicalsociety.org\/guidelinespdf\/1_Treatmentof_HIV_Infected_Adults.pdf(last accessed 15 April 2009) (last accessed 8 October 2008)."},{"key":"e_1_2_13_4_2","doi-asserted-by":"crossref","unstructured":"De RuiterA MerceyD AndersonJet al.British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women.HIV Med2008;9:452\u2013502.","DOI":"10.1111\/j.1468-1293.2008.00619.x"},{"key":"e_1_2_13_5_2","unstructured":"Public Health Service Task Force.Recommendations for use of antiretroviral drugs in pregnant HIV\u2010infected women for maternal healthandinterventions to reduce perinatal HIV transmission in the United States. July 8 2008. Available at:http:\/\/aidsinfo.nih.gov\/contentfiles\/PerinatalGL.pdf(last accessed 10 October 2008)."},{"key":"e_1_2_13_6_2","first-page":"795","article-title":"Intrapartum and neonatal single dose nevirapine compared with zidovudine for the prevention of mother\u2010to\u2010child transmission of HIV\u20101 in Kampala, Uganda","volume":"354","author":"Guay LA","year":"1999","journal-title":"HIVNET 012 Randomised Trial"},{"key":"e_1_2_13_7_2","first-page":"1009","article-title":"Prevalence of resistance to nevirapine in mothers and children after single\u2010dose exposure to prevent vertical transmission of HIV\u20101","volume":"36","author":"Arriv\u00e9 E","year":"2007","journal-title":"a meta-analysis"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/427287"},{"key":"e_1_2_13_9_2","first-page":"380","article-title":"Exposure to antiretroviral therapy in utero or early life","volume":"32","author":"European Collaborative Study.","year":"2003","journal-title":"the health of uninfected children born to HIV-infected women"},{"key":"e_1_2_13_10_2","first-page":"484","article-title":"Combination antiretroviral strategies for the treatment of pregnant HIV\u20101\u2010infected women and prevention of perinatal HIV\u20101 transmission","volume":"29","author":"Cooper ER","year":"2002","journal-title":"J AIDS"},{"key":"e_1_2_13_11_2","first-page":"592","article-title":"Achievements in public health","volume":"55","author":"Centers for Disease Control and Prevention.","year":"2006","journal-title":"reduction in perinatal transmission of HIV infection \u2013 United States, 1985\u20132005"},{"key":"e_1_2_13_12_2","first-page":"1","article-title":"Mother\u2010to\u2010child transmission of HIV\u20101","volume":"124","author":"Foster C","year":"2008","journal-title":"UK strategies for prevention"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f9b67a"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.158.5.422"},{"key":"e_1_2_13_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411033311801"},{"key":"e_1_2_13_16_2","unstructured":"Public Health Service Task Force.Guidelines for the use of antiretroviral agents in HIV\u20101\u2010infected adults and adolescents. January 29 2008. Available athttp:\/\/aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL.pdf(last accessed 1 December 2008)."},{"key":"e_1_2_13_17_2","unstructured":"UNAIDS.Report on the global AIDS epidemic. 2008. Available at:http:\/\/www.unaids.org\/en\/KnowledgeCentre\/HIVData\/GlobalReport\/2008\/2008_Global_report.asp(last accessed 1 December 2008)."},{"issue":"1","key":"e_1_2_13_18_2","first-page":"S4","article-title":"Single\u2010dose nevirapine combined with a short course of combivir for prevention of mother to child transmission of HIV\u20101 can significantly decrease the subsequent development of maternal and infant resistant virus","volume":"10","author":"McIntyre JA","year":"2005","journal-title":"Antivir Ther"},{"key":"e_1_2_13_19_2","first-page":"1698","article-title":"Single\u2010dose tenofovir and emtricitabine for reduction of viral resistance to non\u2010nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention","volume":"370","author":"Chi BH","year":"2007","journal-title":"an open-label randomised trial"},{"key":"e_1_2_13_20_2","unstructured":"World Health Organization.Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Towards universal access. WHO Guidelines 2006. Available at:http:\/\/www.who.int\/hiv\/pub\/guidelines\/pmtctguidelines3.pdf(last accessed 8 October 2008)."},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/503045"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328133884b"},{"key":"e_1_2_13_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm411"},{"key":"e_1_2_13_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200012220-00013"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa991159"},{"key":"e_1_2_13_26_2","first-page":"558","article-title":"Increased rates of preterm delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy","volume":"196","author":"Martin F","year":"2007","journal-title":"a single center cohort study"},{"key":"e_1_2_13_27_2","unstructured":"Antiretroviral Pregnancy Registry International Interim Report 1 January 1989 \u2013 31 July 2008. Issued December 2008. Available at:http:\/\/www.APRegistry.com"},{"key":"e_1_2_13_28_2","first-page":"1472","article-title":"From the FDA","volume":"280","author":"Nightingale SL.","year":"1998","journal-title":"JAMA"},{"key":"e_1_2_13_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-3-11"},{"issue":"2","key":"e_1_2_13_30_2","doi-asserted-by":"crossref","first-page":"M47","DOI":"10.1177\/135965350501002S05","article-title":"Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria","volume":"10","author":"Moyle G.","year":"2005","journal-title":"Antivir Ther"},{"key":"e_1_2_13_31_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.1.3.415"},{"key":"e_1_2_13_32_2","first-page":"716","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir","volume":"46","author":"Birkus G","year":"2002","journal-title":"comparison with other nucleoside reverse transcriptase inhibitors"},{"key":"e_1_2_13_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922204322749530"},{"key":"e_1_2_13_34_2","doi-asserted-by":"publisher","DOI":"10.1385\/CT:5:3:333"},{"key":"e_1_2_13_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/em.20201"},{"key":"e_1_2_13_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200304010-00004"},{"key":"e_1_2_13_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200306010-00010"},{"key":"e_1_2_13_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)07219-0"},{"key":"e_1_2_13_39_2","first-page":"1769","article-title":"Persistent mitochondrial dysfunction in HIV\u20101\u2010exposed but uninfected infants","volume":"17","author":"Barret B","year":"2003","journal-title":"clinical screening in a large prospective cohort"},{"key":"e_1_2_13_40_2","first-page":"261","article-title":"Nucleoside exposure in the children of HIV\u2010infected women receiving antiretroviral drugs","volume":"25","author":"The Perinatal Safety Review Working Group.","year":"2000","journal-title":"absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts"},{"key":"e_1_2_13_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200105250-00023"},{"key":"e_1_2_13_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000086400.93257.74"},{"key":"e_1_2_13_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(03)00005-6"},{"key":"e_1_2_13_44_2","first-page":"323","article-title":"Administration of 9\u2010[2\u2010(R)\u2010(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta)","volume":"20","author":"Tarantal AF","year":"1999","journal-title":"safety and efficacy studies"},{"key":"e_1_2_13_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200203010-00001"},{"key":"e_1_2_13_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1469-1487.2004"},{"key":"e_1_2_13_47_2","first-page":"3144","article-title":"Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy","volume":"52","author":"Van Rompay KK","year":"2008","journal-title":"summary of pharmacokinetics and biological and virological effects"},{"key":"e_1_2_13_48_2","doi-asserted-by":"publisher","DOI":"10.1086\/322781"},{"key":"e_1_2_13_49_2","volume-title":"US Prescribing Information","author":"VIREAD\u00ae (tenofovir disoproxil fumarate) tablets.","year":"2008"},{"key":"e_1_2_13_50_2","unstructured":"WangLH BegleyJ FengJY QuinnJ RousseauF.Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing.14th International AIDS Conference. Barcelona Spain July 2002 [Abstract 4546]."},{"key":"e_1_2_13_51_2","volume-title":"US Prescribing Information","author":"Emtriva\u00ae (emtricitabine) capsules.","year":"2008"},{"key":"e_1_2_13_52_2","unstructured":"HawkinsT VeikleyW St.ClaireRet al. Intracellular pharmacokinetics of tenofovir\u2010DP and carbovir\u2010TP in patients receiving triple nucleoside regimens.5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome Italy April 2004 [Abstract 5.11]."},{"key":"e_1_2_13_53_2","unstructured":"BonoraS Gonzalez de RequenaD ChiesaE et al.and the Target Study Group. Transplacental passage of tenofovir and other antiretrovirals at delivery.14th Conference on Retroviruses and Opportunistic Infections Los Angeles CA February 2007 [Abstract 738a]."},{"key":"e_1_2_13_54_2","unstructured":"BurchettS BestB MirochnickMet al.and the PACTG P1026s Team. Tenofovir pharmacokinetics during pregnancy at delivery and postpartum.14th Conference on Retroviruses and Opportunistic Infections Los Angeles CA February 2007 [Abstract 738b]."},{"key":"e_1_2_13_55_2","unstructured":"RodmanJ FlynnP ShapiroDet al.and PACTG 394 Study Team.Pharmacokinetics (PK) and safety of tenofovir disoproxil fumarate (TDF) in HIV\u20101\u2010infected pregnant women and their infants.13th Conference on Retroviruses and Opportunistic Infections Denver CO February 2006 [Abstract 708]."},{"key":"e_1_2_13_56_2","doi-asserted-by":"crossref","unstructured":"HirtD UrienS ReyEet al.Population pharmacokinetics of tenofovir in HIV\u20101\u2010infected pregnant women and their neonates:TEmAA ANRS 12109.15th Conference on Retroviruses and Opportunistic Infections Boston MA February 2008 [Abstract 47LB].","DOI":"10.1038\/clpt.2008.201"},{"key":"e_1_2_13_57_2","doi-asserted-by":"crossref","unstructured":"ArriveE ChaixML NerrienetEet al. The TEmAA ANRS 12109 phase II trial step 1: tolerance and viral resistance after single dose nevirapine and short course of tenofovir disoproxil fumarate and emtricitabine to prevent mother\u2010to\u2010child transmission of HIV\u20101.15th Conference on Retroviruses and Opportunistic Infections Boston MA February 2008 [Abstract 45b].","DOI":"10.1186\/1742-4690-5-S1-O20"},{"key":"e_1_2_13_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328216f15b"},{"issue":"1","key":"e_1_2_13_59_2","first-page":"26","article-title":"Renal tubular dysfunction associated with tenofovir\u2010based HAART in perinatally acquired HIV","volume":"9","author":"Onyeador N","year":"2008","journal-title":"the need for paediatric formulations and pharmacokinetic studies"},{"key":"e_1_2_13_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2006.00369.x"},{"key":"e_1_2_13_61_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318032bbee"},{"key":"e_1_2_13_62_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629060-00002"},{"key":"e_1_2_13_63_2","doi-asserted-by":"publisher","DOI":"10.1258\/095646206777323346"},{"key":"e_1_2_13_64_2","first-page":"492","article-title":"Efavirenz vs. nevirapine in current clinical practice","volume":"35","author":"Manfredi R","year":"2004","journal-title":"a prospective, open-label observational study"},{"key":"e_1_2_13_65_2","volume-title":"US Prescribing Information","author":"Sustiva\u00ae (efavirenz).","year":"2008"},{"key":"e_1_2_13_66_2","volume-title":"Summary of Product Characteristics (December 2008)","author":"ATRIPLA\u00ae.","year":"2008"},{"key":"e_1_2_13_67_2","volume-title":"US Prescribing Information","author":"ATRIPLA\u00ae (efavirenz\/emtricitabine\/tenofovir disoproxil fumarate) tablets.","year":"2008"},{"key":"e_1_2_13_68_2","doi-asserted-by":"crossref","unstructured":"BequetR. Universal antiretroviral therapy for pregnant and breastfeeding HIV\u2010infected women: towards elimination of mother\u2010to\u2010child transmission of HIV\u20101 in resource limited settings.5th Dominique Dormont International Conference. Paris France March 2009 [Abstract L7].","DOI":"10.1186\/1742-4690-6-S1-L7"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00709.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00709.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:52:07Z","timestamp":1696866727000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00709.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,8]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00709.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00709.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,8]]}}}